LUCENTIS

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug LUCENTIS contains one active pharmaceutical ingredient (API):

1 Ranibizumab UNII ZL1R02VT79 - RANIBIZUMAB

Ranibizumab is a humanised recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A (VEGF-A). It binds with high affinity to the VEGF-A isoforms, thereby preventing binding of VEGF-A to its receptors VEGFR-1 and VEGFR-2. Binding of VEGF-A to its receptors leads to endothelial cell proliferation and neovascularisation, as well as vascular leakage, all of which are thought to contribute to the progression of the neovascular form of age-related macular degeneration, pathologic myopia and CNV or to visual impairment caused by either diabetic macular oedema or macular oedema secondary to RVO in adults and retinopathy of prematurity in preterm infants. Read about Ranibizumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LUCENTIS Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
S01LA04	Ranibizumab	S Sensory organs → S01 Ophthalmologicals → S01L Ocular vascular disorder agents → S01LA Antineovascularisation agents
Discover more medicines within S01LA04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 10138N, 10373Y, 10374B, 11471R, 11480F, 11975G, 11981N, 1382R
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 526515080085503, 526518030092303, 526529502157216
Country: CA	Health Products and Food Branch	Identifier(s): 02296810, 02425629
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 27.954-04-08
Country: EE	Ravimiamet	Identifier(s): 1299933, 1664669
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 106374003, 106374004
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 387375, 538757
Country: FR	Base de données publique des médicaments	Identifier(s): 64339586
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 140395, 246076
Country: HK	Department of Health Drug Office	Identifier(s): 55638, 63860, 65166
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 6036, 8634
Country: IT	Agenzia del Farmaco	Identifier(s): 037608015, 037608027, 037608039, 037608041, 037608054
Country: JP	医薬品医療機器総合機構	Identifier(s): 1319403A1036, 1319403G1020
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1071582, 1075419, 1084489
Country: NL	Z-Index G-Standaard	Identifier(s): 16016610
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 116424, 87092
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 12442
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100165086
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W51850002
Country: SG	Health Sciences Authority	Identifier(s): 13411P, 14772P
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 10283321H
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699504770254, 8699504770353
Country: US	FDA, National Drug Code	Identifier(s): 50242-080, 50242-082
Country: ZA	Health Products Regulatory Authority	Identifier(s): 41/15.4/0860